Stereotaxis, Inc. STXS

Company Overview

Stereotaxis, Inc. is a U.S.-based medical technology company focused on robotic systems for minimally invasive endovascular procedures, primarily in the field of cardiac electrophysiology. The company develops robotic magnetic navigation and interventional technologies designed to improve precision, stability, and physician control during catheter-based procedures. Stereotaxis operates within the broader medical devices, robotic surgery, and electrophysiology industries, with its revenue primarily generated through capital equipment sales, recurring disposables and service contracts, and technology licensing arrangements.

The company’s principal platforms include the Genesis Robotic Magnetic Navigation System, robotic drive technologies, navigation software, and related procedural devices used in catheter ablation and interventional procedures. Stereotaxis serves hospitals, academic medical centers, and electrophysiology laboratories globally, particularly institutions performing complex arrhythmia treatments. The company’s strategic positioning is centered on robotic precision, reduced physician radiation exposure, and improved catheter stability compared with conventional manual navigation systems. Founded in 1990 and headquartered in St. Louis, Missouri, Stereotaxis evolved from magnetic guidance research into a specialized robotic healthcare technology provider focused on endovascular robotics and minimally invasive navigation systems.

Business Operations

Stereotaxis generates revenue through sales and installations of robotic systems, recurring service agreements, disposables, and software-related products. Its core operating focus centers on the Genesis platform and associated robotic technologies, including the MAGiC catheter drive system, navigation interfaces, and procedural software applications. The company also develops vascular and electrophysiology-related devices through internal research and strategic partnerships. Revenue has historically included a mix of system placements in hospitals and long-term service and maintenance contracts tied to installed systems.

The company operates in both domestic and international markets, with installations across North America, Europe, Asia-Pacific, and selected markets in the Middle East. Stereotaxis maintains relationships with healthcare institutions, distributors, and technology collaborators to expand procedural capabilities and adoption. The company has also pursued integration efforts with mapping and imaging systems commonly used in electrophysiology labs. Public disclosures identify partnerships and collaborations with medical device and imaging companies intended to enhance interoperability and workflow efficiency within robotic catheter navigation procedures.

Strategic Position & Investments

Stereotaxis has positioned itself around the long-term adoption of robotic endovascular intervention technologies, with a strategic emphasis on expanding beyond electrophysiology into broader vascular applications. Growth initiatives have included development of next-generation robotic platforms, enhanced procedural automation, digital workflow software, and robotics-enabled interventional devices. The company has also focused on reducing installation complexity and improving system scalability to increase adoption among hospitals and electrophysiology centers.

Recent strategic efforts have included investments in robotic catheter technologies, mapping integration capabilities, and adjacent interventional robotics applications. Stereotaxis has highlighted development programs related to robotic endovascular navigation and minimally invasive surgical robotics through internal R&D and targeted acquisitions. The company acquired Access Point Technologies EP, Inc., a developer of electrophysiology devices, to strengthen its portfolio of proprietary catheters and interventional tools. Public filings and investor materials also indicate ongoing investment in autonomous navigation capabilities, robotics software, and expanded procedural indications intended to support long-term growth in robotic-assisted endovascular medicine.

Geographic Footprint

Stereotaxis is headquartered in St. Louis, Missouri, and maintains a global commercial footprint through direct operations and distributor networks. The company’s installed base spans hospitals and medical centers across the United States, Europe, and parts of Asia-Pacific, with notable activity in countries that have established electrophysiology and catheter ablation markets. International placements and service operations remain important to the company’s recurring revenue model.

The company’s technologies have been deployed in academic and high-volume cardiac centers across multiple continents, reflecting a strategy focused on specialized healthcare institutions capable of advanced electrophysiology procedures. Stereotaxis has also pursued broader international expansion through regional partnerships and regulatory approvals supporting commercial activity outside the United States. Data regarding precise market share by region remains limited in public disclosures, though international operations are consistently identified as a material component of the company’s commercial strategy.

Leadership & Governance

Stereotaxis is led by executives with backgrounds in healthcare technology, finance, and medical device commercialization. The company’s governance structure follows a public-company board and executive leadership model typical of Nasdaq-listed medical technology firms. Strategic messaging from leadership has emphasized advancing robotic medicine, improving procedural safety and precision, and expanding robotic applications beyond cardiac electrophysiology into broader minimally invasive interventions.

Key executives include:

• David Fischel – Chairman and Chief Executive Officer
• Mladen Stoyanov – Chief Financial Officer
• Evan Tiner – Chief Operating Officer
• Bevil Hogg – Senior Vice President and Chief Legal Officer

Leadership communications in public filings and investor presentations consistently emphasize innovation in robotic navigation, physician workflow efficiency, and long-term expansion of robotic-assisted endovascular procedures through technology development and global commercialization efforts.